查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1970624

全球磺胺類藥物市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Sulphonamides Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 166 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計磺胺類藥物市場規模將從 2025 年的 1.472 億美元成長到 2034 年的 2.327 億美元，2026 年至 2034 年的複合年成長率為 5.22%。

磺胺類藥物市場持續發展，因為這些抗菌藥物在治療人類和動物感染疾病仍然發揮著至關重要的作用。儘管新型抗生素不斷湧現，但由於磺胺類藥物藥物價格低廉、穩定性良好且對多種細菌病原體有效，因此仍被廣泛使用。其應用範圍涵蓋獸醫學、農業和藥物製劑等領域。

研究進展正推動新型磺胺類藥物衍生物的開發，這些衍生物具有更優的藥物動力學特性和更低的抗藥性。聯合治療也在探索之中，旨在提高療效並應對抗生素抗藥性帶來的新挑戰。磺胺類藥物的多功能性使其在藥物合成中確立了基本結構和化學中間體的地位。

全球需求主要受獸藥市場擴張、複方藥物監管核准、農業領域持續應用等因素驅動。磺胺類藥物藥物市場預計將繼續在全球抗生素市場中保持強勁勢頭，並在傳統與創新之間取得平衡。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球磺胺類藥物市場：依給藥途徑分類

  • 市場分析、洞察與預測
  • 口服
  • 外用
  • 其他給藥途徑

第5章 全球磺胺類藥物市場：依應用分類

  • 市場分析、洞察與預測
  • 皮膚感染疾病
  • 胃腸道感染疾病（GIT感染疾病）
  • 尿道感染（UTI）
  • 呼吸道感染疾病（RTI）
  • 其他用途

第6章 全球磺胺類藥物藥物市場：依藥物類型分類

  • 市場分析、洞察與預測
  • 原藥
  • 學名藥

第7章 全球磺胺類藥物市場：依分銷管道分類

  • 市場分析、洞察與預測
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第8章 全球磺胺類藥物市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第9章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第10章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Allergan
    • Amneal Pharmaceuticals LLC
    • Aurobindo Pharma
    • Bausch & Lomb Incorporated
    • Cadila Pharmaceuticals Ltd
    • Cipla Ltd
    • Dr. Reddy'S Laboratories
    • F. Hoffmann-La Roche Ltd
    • GSK PLC
    • Glenmark Pharma Ltd
    • Lexine Technochem Pvt. Ltd
    • Monarch Pharmaceuticals
簡介目錄
Product Code: VMR11219829

The Sulphonamides Market size is expected to reach USD 232.70 Million in 2034 from USD 147.20 Million (2025) growing at a CAGR of 5.22% during 2026-2034.

The sulphonamides market continues to evolve as these antibacterial agents remain relevant in treating infections across humans and animals. Despite the availability of newer antibiotics, sulphonamides are widely used due to their affordability, stability, and effectiveness against a range of bacterial pathogens. Their application extends into veterinary medicine, agriculture, and pharmaceutical formulations.

Research is advancing the development of novel sulphonamide derivatives with improved pharmacokinetics and reduced resistance. Combination therapies are being explored to extend efficacy and address emerging antimicrobial resistance challenges. The versatility of sulphonamides also positions them as building blocks in drug synthesis and chemical intermediates.

Global demand will be supported by expanding veterinary care, regulatory approvals for combination drugs, and sustained use in agriculture. The sulphonamides market is expected to remain a resilient segment within the global antibiotic landscape, balancing tradition with innovation.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Route Of Administration

  • Oral
  • Topical
  • Other Routes Of Administration

By Application

  • Skin Infection
  • Gastrointestinal (GIT) Infection
  • Urinary Tract Infection (UTI)
  • Respiratory Tract Infection (RTI)
  • Other Applications

By Medication Type

  • Branded
  • Generics

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

COMPANIES PROFILED

  • Allergan, Amneal Pharmaceuticals LLC, Aurobindo Pharma, Bausch Lomb Incorporated, Cadila Pharmaceuticals Ltd, Cipla Ltd, Dr Reddys Laboratories, F HoffmannLa Roche Ltd, GSK PLC, Glenmark Pharma Ltd, Lexine Technochem Pvt Ltd, Monarch Pharmaceuticals
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL SULPHONAMIDES MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN and Kilo Tons)

  • 4.1. Market Analysis, Insights and Forecast Route Of Administration
  • 4.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)
  • 4.3. Topical Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)
  • 4.4. Other Routes Of Administration Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)

Chapter 5. GLOBAL SULPHONAMIDES MARKET: BY APPLICATION 2022-2034 (USD MN and Kilo Tons)

  • 5.1. Market Analysis, Insights and Forecast Application
  • 5.2. Skin Infection Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)
  • 5.3. Gastrointestinal (GIT) Infection Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)
  • 5.4. Urinary Tract Infection (UTI) Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)
  • 5.5. Respiratory Tract Infection (RTI) Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)
  • 5.6. Other Applications Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)

Chapter 6. GLOBAL SULPHONAMIDES MARKET: BY MEDICATION TYPE 2022-2034 (USD MN and Kilo Tons)

  • 6.1. Market Analysis, Insights and Forecast Medication Type
  • 6.2. Branded Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)
  • 6.3. Generics Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)

Chapter 7. GLOBAL SULPHONAMIDES MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN and Kilo Tons)

  • 7.1. Market Analysis, Insights and Forecast Distribution Channel
  • 7.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)
  • 7.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)
  • 7.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN and Kilo Tons)

Chapter 8. GLOBAL SULPHONAMIDES MARKET: BY REGION 2022-2034(USD MN and Kilo Tons)

  • 8.1. Regional Outlook
  • 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Kilo Tons)
    • 8.2.1 By Route Of Administration
    • 8.2.2 By Application
    • 8.2.3 By Medication Type
    • 8.2.4 By Distribution Channel
    • 8.2.5 United States
    • 8.2.6 Canada
    • 8.2.7 Mexico
  • 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Kilo Tons)
    • 8.3.1 By Route Of Administration
    • 8.3.2 By Application
    • 8.3.3 By Medication Type
    • 8.3.4 By Distribution Channel
    • 8.3.5 United Kingdom
    • 8.3.6 France
    • 8.3.7 Germany
    • 8.3.8 Italy
    • 8.3.9 Russia
    • 8.3.10 Rest Of Europe
  • 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Kilo Tons)
    • 8.4.1 By Route Of Administration
    • 8.4.2 By Application
    • 8.4.3 By Medication Type
    • 8.4.4 By Distribution Channel
    • 8.4.5 India
    • 8.4.6 Japan
    • 8.4.7 South Korea
    • 8.4.8 Australia
    • 8.4.9 South East Asia
    • 8.4.10 Rest Of Asia Pacific
  • 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Kilo Tons)
    • 8.5.1 By Route Of Administration
    • 8.5.2 By Application
    • 8.5.3 By Medication Type
    • 8.5.4 By Distribution Channel
    • 8.5.5 Brazil
    • 8.5.6 Argentina
    • 8.5.7 Peru
    • 8.5.8 Chile
    • 8.5.9 South East Asia
    • 8.5.10 Rest of Latin America
  • 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Kilo Tons)
    • 8.6.1 By Route Of Administration
    • 8.6.2 By Application
    • 8.6.3 By Medication Type
    • 8.6.4 By Distribution Channel
    • 8.6.5 Saudi Arabia
    • 8.6.6 UAE
    • 8.6.7 Israel
    • 8.6.8 South Africa
    • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

  • 9.1. Recent Developments
  • 9.2. Company Categorization
  • 9.3. Supply Chain & Channel Partners (based on availability)
  • 9.4. Market Share & Positioning Analysis (based on availability)
  • 9.5. Vendor Landscape (based on availability)
  • 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL SULPHONAMIDES INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Company Profiles
    • 10.2.1 Allergan
    • 10.2.2 Amneal Pharmaceuticals LLC
    • 10.2.3 Aurobindo Pharma
    • 10.2.4 Bausch & Lomb Incorporated
    • 10.2.5 Cadila Pharmaceuticals Ltd
    • 10.2.6 Cipla Ltd
    • 10.2.7 Dr. Reddy'S Laboratories
    • 10.2.8 F. Hoffmann-La Roche Ltd
    • 10.2.9 GSK PLC
    • 10.2.10 Glenmark Pharma Ltd
    • 10.2.11 Lexine Technochem Pvt. Ltd
    • 10.2.12 Monarch Pharmaceuticals